1 week Ago By ABMN Staff
Legal & General Group Plc increased its position in shares of GeneDx Holdings Corp. ( NASDAQ:WGS – Free Report ) by 31.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission.
The institutional investor owned 11,123 shares of the company’s stock after acquiring an additional 2,638 shares during the period. Legal & General Group Plc’s holdings in GeneDx were worth $855,000 at the end of the most recent quarter. A number of other hedge funds and other institutional investors also recently bought and sold shares of the company.
Vanguard Group Inc. boosted its holdings in GeneDx by 18.5% during the 4th quarter.
Vanguard Group Inc. now owns 1,006,210 shares of the company’s stock valued at $77,337,000 after acquiring an additional 156,768 shares during the period. William Blair Investment Management LLC purchased a new position in GeneDx during the 4th quarter valued at about $51,496,000.
Geode Capital Management LLC boosted its holdings in GeneDx by 1.2% during the 4th quarter. Geode Capital Management LLC now owns 382,350 shares of the company’s stock valued at $29,396,000 after acquiring an additional 4,719 shares during the period.
Zweig DiMenna Associates LLC purchased a new position in GeneDx during the 4th quarter valued at about $23,788,000. Finally, Raymond James Financial Inc. purchased a new position in GeneDx during the 4th quarter valued at about $20,371,000.
61.72% of the stock is currently owned by hedge funds and other institutional investors. Wall Street Analysts Forecast Growth A number of equities analysts recently commented on the company.
TD Cowen raised their target price on GeneDx from $75.00 to $118.00 and gave the company a “buy” rating in a report on Tuesday, January 7th.
The Goldman Sachs Group lifted their price objective on GeneDx from $70.00 to $80.00 and gave the company a “neutral” rating in a research note on Wednesday, February 19th.
Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $72.33.
Insider Transactions at GeneDx In other GeneDx news, CFO Kevin Feeley sold 402 shares of GeneDx stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $90.05, for a total transaction of $36,200.
10. Following the transaction, the chief financial officer now owns 5,044 shares of the company’s stock, valued at $454,212.20.
The trade was a 7.38 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink .
Also, CEO Katherine Stueland sold 1,657 shares of GeneDx stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $78.48, for a total value of $130,041.
36. Following the transaction, the chief executive officer now directly owns 3,937 shares in the company, valued at approximately $308,975.76.
This trade represents a 29.62 % decrease in their position. The disclosure for this sale can be found here .
In the last 90 days, insiders have sold 138,780 shares of company stock valued at $12,907,437. Corporate insiders own 27.30% of the company’s stock.
GeneDx Stock Performance Shares of WGS opened at $111.01 on Monday. The company has a debt-to-equity ratio of 0.
25, a quick ratio of 2.27 and a current ratio of 2.40.
GeneDx Holdings Corp. has a 1 year low of $10.70 and a 1 year high of $115.
60. The stock has a market capitalization of $3.12 billion, a PE ratio of -56.
64 and a beta of 1.93. The stock has a 50-day simple moving average of $95.
78 and a 200-day simple moving average of $82.00. GeneDx ( NASDAQ:WGS – Get Free Report ) last issued its earnings results on Tuesday, February 18th.
The company reported $0.70 earnings per share for the quarter, topping the consensus estimate of $0.04 by $0.
66. GeneDx had a positive return on equity of 3.33% and a negative net margin of 17.
12%. The business had revenue of $95.64 million for the quarter, compared to analyst estimates of $82.
24 million. On average, analysts predict that GeneDx Holdings Corp. will post 0.
97 earnings per share for the current fiscal year. GeneDx Profile ( Free Report ) GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services.
The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights. Featured Stories Want to see what other hedge funds are holding WGS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GeneDx Holdings Corp.
( NASDAQ:WGS – Free Report ). Receive News & Ratings for GeneDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GeneDx and related companies with MarketBeat.com's FREE daily email newsletter .
.
